LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
University of Turin
Turín, ItaliaPublicaciones en colaboración con investigadores/as de University of Turin (27)
2023
-
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
JTO Clinical and Research Reports, Vol. 4, Núm. 1
-
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
Clinical Lung Cancer, Vol. 24, Núm. 5, pp. 415-428
-
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
The Lancet, Vol. 401, Núm. 10378, pp. 733-746
2022
-
Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform
Scientific Reports, Vol. 12, Núm. 1
-
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Nature medicine, Vol. 28, Núm. 4, pp. 752-765
2021
-
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
European Journal of Cancer, Vol. 151, pp. 211-220
2020
-
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy
Journal of Thoracic Oncology, Vol. 15, Núm. 5, pp. 709-740
-
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
Radiotherapy and Oncology, Vol. 149, pp. 84-88
2019
-
Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119
-
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts
Radiotherapy and Oncology, Vol. 133, pp. 163-166
2018
-
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
Journal of Thoracic Oncology, Vol. 13, Núm. 2, pp. 165-183
-
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
Clinical Lung Cancer, Vol. 19, Núm. 4, pp. 331-339
2017
-
Lung cancer: current therapies and new targeted treatments
The Lancet, Vol. 389, Núm. 10066, pp. 299-311
-
Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer
Lung Cancer, Vol. 104, pp. 45-51
-
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies
Clinical Lung Cancer, Vol. 18, Núm. 5, pp. 489-496
2016
-
Clinicopathologic features of advanced squamous NSCLC
Journal of Thoracic Oncology, Vol. 11, Núm. 9, pp. 1411-1422
-
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment
Journal of Thoracic Oncology, Vol. 11, Núm. 12, pp. 2066-2081
-
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
ESMO Open, Vol. 1, Núm. 6
2015
-
2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer
Annals of Oncology, Vol. 26, Núm. 8, pp. 1573-1588
-
Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
Journal of Thoracic Oncology, Vol. 10, Núm. 12, pp. 1745-1753